Clinical trial Recruiting at 1 site Observational Ages 15 to 50 Women only

Evaluating the effects of BRIUMVI® on pregnancy outcomes in women with Multiple Sclerosis

Official title: BRIUMVI® Pregnancy Registry: A Prospective Study of Pregnancy and Infant Outcomes in Patients Treated With BRIUMVI®

Run by TG Therapeutics, Inc. · NCT06433765 · Data updated 2026-11-12

This study is trying to see if using BRIUMVI® during pregnancy affects the health of babies born to women with Multiple Sclerosis compared to those who didn’t use the medication.

More Multiple Sclerosis trials

Quick facts

Study typeObservational
Ages15 Years to 50 Years
SexWomen only
Enrollment728 (estimated)
SponsorTG Therapeutics, Inc.
Industry-sponsored
Locations1 site (Wilmington, North Carolina)
StatusRecruiting
StartedJune 1, 2024
Main results expectedMarch 31, 2035
Study endsMarch 31, 2035
Registry record updatedOctober 29, 2026
Trial IDNCT06433765 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include pregnant women diagnosed with Multiple Sclerosis who have either been exposed to BRIUMVI® or have not been exposed during their pregnancy.

Probably not a fit

Patients who have been exposed to anti-CD20 monoclonal antibodies or known teratogens during pregnancy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to compare the prevalence of major congenital malformations in two groups of pregnant women with Multiple Sclerosis (MS): those who have been exposed to BRIUMVI® (Ublituximab) and those who have not. Participants must have a diagnosis of MS and be currently or recently pregnant. The study will collect data from a registry to assess the outcomes of pregnancies in these cohorts, focusing on the safety of BRIUMVI® during pregnancy.

Why it matters

Potential benefit: If successful, this study could provide critical insights into the safety of BRIUMVI® during pregnancy, potentially guiding treatment decisions for pregnant women with MS.

How similar studies have gone: While studies on the effects of medications during pregnancy are common, this specific evaluation of BRIUMVI® in pregnant women with MS is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. For exposed cohort: Participant exposed to at least 1 dose of BRIUMVI®.
2. For unexposed cohort: Participants not exposed to BRIUMVI® at any time during the pregnancy.
3. Diagnosis of MS.
4. Currently or recently (within 1 year of pregnancy outcome) pregnant.
5. Authorization from healthcare provider to provide data to registry.

Exclusion Criteria:

1. Prior to enrollment, participant has exposure to anti-CD20 monoclonal antibodies at any time during pregnancy.
2. Occurrence of pregnancy outcome prior to first contact with the virtual research coordination center (VRCC) (retrospectively enrolled).
3. Exposure to known teratogens and/or investigational medications during pregnancy.

Where it's running

  • BRIUMVI® Pregnancy Registry Virtual Research Coordination Center
    Wilmington, North Carolina, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.